Optogenetic Neuromodulation of the Spinal Cord for Chronic Pain Relief in a Rat Model

Introduction: Chronic pain is a pervasive and challenging clinical issue that affects millions globally and places considerable strain on healthcare systems. Conventional treatment options often yield suboptimal results, with limited efficacy and undesirable side effects. Recent advances in optogenetics have enabled the precise modulation of neural activity through the genetic introduction of light-sensitive proteins, such as channelrhodopsins, into targeted neuronal populations. This technology allows researchers to specifically control inhibitory or excitatory circuits in the spinal cord, a critical hub in pain transmission, thereby offering a highly selective and minimally invasive approach to pain management. By leveraging state-of-the-art gene delivery techniques and optogenetic stimulation, studies have demonstrated that modulation of spinal cord circuits can effectively attenuate pain responses in preclinical models. These findings underscore the substantial potential of optogenetic neuromodulation as a novel therapeutic avenue for chronic pain, signifying a significant step toward the development of more effective and individualized pain management strategies.

Methods: We utilized Multi-Characteristic Opsin (MCO) and implanted optogenetic stimulators (O-IPG) to sensitize and modulate inhibitory neurons in the spine in a model of chronic pain. MCO was introduced to the lumbar spine via Nano-Enhanced Optical Delivery using a fiber coupled laser in a 25G needle. A mixture of MCO-encoding DNA and functionalized Gold Nanorods was injected into the lumbar spine via the L5-L6 junction and irradiated using the fiber coupled laser. The sensitized neurons were controlled via an overlying implanted device which delivered controlled light pulses activate inhibitory targeted neurons in the model animals. Behavioral pain assessments in chronic nerve injury pain models (e.g., mechanical allodynia, thermal hyperalgesia) before and after stimulation were used to establish the efficacy of optogenetic stimulation.

Results: Our results demonstrated that there was a significant elevation in the 50% paw withdrawal threshold and thermal stimulation withdrawal times from a heated probe with optogenetic stimulation. The hypersensitivity that results from nerve injury was compensated for when 5Hz optogenetic stimulation pulses were applied. In the low dose group, this level of stimulation had no significant effect on the sensory responses of the experimental animals, strongly supporting the role of optimal opsin expression in the efficacy of therapy. The lack of enhanced effect in the higher dose groups suggests that there is a minimal threshold that can be reached beyond which there is no clinically relevant advantage.

Conclusion: Optogenetic neuromodulation of spinal neurons demonstrates promising potential for precise and effective chronic pain management, paving the way for future translational research.